国际妇产科学杂志
國際婦產科學雜誌
국제부산과학잡지
JOURNAL OF INTERNATIONAL OBSTETRICS AND GYNECOLOGY
2015年
4期
457-460
,共4页
卵巢肿瘤%肿瘤转移%肿瘤标记,生物学%治疗
卵巢腫瘤%腫瘤轉移%腫瘤標記,生物學%治療
란소종류%종류전이%종류표기,생물학%치료
Ovarian neoplasms%Neoplasms metastasis%Tumor markers,biological%Therapy
卵巢恶性肿瘤是女性生殖系统三大恶性肿瘤之一,其死亡率居妇科肿瘤的首位,已成为威胁女性健康的重要杀手。据美国国立癌症研究院调查显示,卵巢癌是与肿瘤相关的女性五大死因之一。上皮性卵巢癌占全部卵巢癌病例的近90%,且病情进展迅速,但由于缺乏早期临床表现和特异性症状,大多数患者就诊时已是晚期,手术治疗困难,预后较差。近年卵巢癌的发病率呈逐年上升趋势,易早期转移及浸润,是造成其死亡率高的原因。卵巢癌转移等恶性生物学行为已成为其研究热点。早期发现有效的卵巢癌转移相关分子标记物并对其进行靶向治疗是提高卵巢癌患者生存率的重要方法。除目前临床应用的糖类蛋白125(CA125)外,跨膜糖蛋白(CD44)、E-钙黏蛋白和E盒结合锌指蛋白1(ZEB1)等生物学分子有望成为诊断卵巢癌早期转移的分子标记物。
卵巢噁性腫瘤是女性生殖繫統三大噁性腫瘤之一,其死亡率居婦科腫瘤的首位,已成為威脅女性健康的重要殺手。據美國國立癌癥研究院調查顯示,卵巢癌是與腫瘤相關的女性五大死因之一。上皮性卵巢癌佔全部卵巢癌病例的近90%,且病情進展迅速,但由于缺乏早期臨床錶現和特異性癥狀,大多數患者就診時已是晚期,手術治療睏難,預後較差。近年卵巢癌的髮病率呈逐年上升趨勢,易早期轉移及浸潤,是造成其死亡率高的原因。卵巢癌轉移等噁性生物學行為已成為其研究熱點。早期髮現有效的卵巢癌轉移相關分子標記物併對其進行靶嚮治療是提高卵巢癌患者生存率的重要方法。除目前臨床應用的糖類蛋白125(CA125)外,跨膜糖蛋白(CD44)、E-鈣黏蛋白和E盒結閤鋅指蛋白1(ZEB1)等生物學分子有望成為診斷卵巢癌早期轉移的分子標記物。
란소악성종류시녀성생식계통삼대악성종류지일,기사망솔거부과종류적수위,이성위위협녀성건강적중요살수。거미국국립암증연구원조사현시,란소암시여종류상관적녀성오대사인지일。상피성란소암점전부란소암병례적근90%,차병정진전신속,단유우결핍조기림상표현화특이성증상,대다수환자취진시이시만기,수술치료곤난,예후교차。근년란소암적발병솔정축년상승추세,역조기전이급침윤,시조성기사망솔고적원인。란소암전이등악성생물학행위이성위기연구열점。조기발현유효적란소암전이상관분자표기물병대기진행파향치료시제고란소암환자생존솔적중요방법。제목전림상응용적당류단백125(CA125)외,과막당단백(CD44)、E-개점단백화E합결합자지단백1(ZEB1)등생물학분자유망성위진단란소암조기전이적분자표기물。
Ovarian malignant tumor is one of the three big malignant tumor in female reproductive system, the mortality rate is highest in gynecological tumors, which has become a serious threat to the female body health. According to the research of National Cancer Institute, ovarian cancer is one of the five female causes of death related to tumor. Epithelial ovarian cancer accounts for nearly 90%of all cases of ovarian cancer, and progress rapidly, but due to the lack of early clinical manifestations and specific symptoms, most are already late, when the patients see the doctors, surgery is difficult, and prognosis is poor. In recent years, there is an upward trend in the incidence of ovarian cancer, and it is easy to early metastasis and infiltration, which was the cause of the high mortality rate. Research on ovarian cancer metastasis of the malignant biological behavior has become a hot field. The early detection of effective ovarian cancer transfer related molecular markers and their targeted therapy is an important way to improve the survival rate of patients with ovarian cancer. In addition to the current clinical application of CA125 ,CD44,E-cadherin and ZEB1 is expected to become the molecular marker of early diagnosis of ovarian cancer metastasis.